Ovid Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Ovid Therapeutics es Meg Alexander , nombrado en Sep 2024, tiene una permanencia de 1.92 años. compensación anual total es $1.02M, compuesta por 50.4% salario y 49.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.032% de las acciones de la empresa, por valor de $180.94K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 3.7 años, respectivamente.
Información clave
Meg Alexander
Chief Executive Officer (CEO)
US$1.0m
Compensación total
| Porcentaje del salario del CEO | 50.38% |
| Permanencia del CEO | 1.9yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 1.4yrs |
| Promedio de permanencia en la Junta Directiva | 3.7yrs |
Actualizaciones recientes de la dirección
Recent updates
OVID: Phase 1 Psychosis Program Will Drive Future Repricing Potential
Analysts have raised the price target for Ovid Therapeutics to $7 from $5, citing updated cash flow models that incorporate expected revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the Phase 1 initiation of OV4071. What’s in the News for Ovid Therapeutics On July 6, 2026, Ovid Therapeutics appointed Charles Carter as Chief Financial Officer, following a mutual agreement for former Chief Business and Financial Officer Jeffrey Rona to transition out of his roles.Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OVID: Index Inclusion And New Psychosis Indications Will Support Bullish Outlook
Analysts have raised their price target on Ovid Therapeutics stock from $5 to $7, citing updated cash flow models that now factor in potential revenue from Lewy Body Dementia Psychosis and Parkinson's Disease Psychosis indications following the start of a Phase 1 study of OV4071. What's in the News for Ovid Therapeutics Ovid Therapeutics added to the S&P Biotechnology Select Industry Index, reflecting inclusion in a widely followed biotech industry benchmark.Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders
Summary Ovid Therapeutics receives a "Hold" rating as it pivots pipeline focus after soticlestat trial failures in rare epileptic syndromes. OVID reported positive phase 1 results for OV329, a next-generation GABA-AT inhibitor targeting drug-resistant focal onset seizures, with phase 2a trials planned for 2026. Pipeline includes KCC2 activators OV350 (IV) and OV4071 (oral) for neurological and psychiatric disorders, with key data and regulatory milestones expected through 2026. Recent financing extends OVID's cash runway into 2028, but clinical and regulatory risks remain for OVID's early-stage programs. Read the full article on Seeking AlphaOvid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Results from the phase 3 Skyway study, using soticlestat for the treatment of patients with Lennox-Gastaut Syndrome, expected by or before September 2024. The global Lennox-Gastaut Syndrome market is expected to reach $1 billion by 2030. Read the full article on Seeking AlphaWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Ovid Therapeutics press release (NASDAQ:OVID): Q2 GAAP EPS of -$0.21 beats by $0.04. Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 millionWe Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$34m |
| Mar 31 2026 | n/a | n/a | -US$24m |
| Dec 31 2025 | US$1m | US$515k | -US$17m |
| Sep 30 2025 | n/a | n/a | -US$36m |
| Jun 30 2025 | n/a | n/a | -US$38m |
| Mar 31 2025 | n/a | n/a | -US$24m |
| Dec 31 2024 | US$2m | US$484k | -US$26m |
Compensación vs. Mercado: La compensación total de Meg($USD1.02M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Meg ha sido consistente con los resultados de la empresa en el último año.
CEO
Meg Alexander (45 yo)
Ms. Margaret Alexander, also known as Meg, is CEO of Ovid Therapeutics Inc. from January 1, 2026 and serves as its President since September 2024 and served as Chief Strategy Officer since June 2023 until...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.3yrs | US$1.93m | 1.93% $ 11.0m | |
| CEO, President & Director | 1.9yrs | US$1.02m | 0.032% $ 180.9k | |
| Advisor | less than a year | US$969.16k | 0.081% $ 465.3k | |
| CFO, Principal Financial Officer | less than a year | sin datos | 0.0051% $ 29.3k | |
| Chief Scientific Officer | 3.2yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 5.1yrs | sin datos | sin datos | |
| Head of Epilepsy Research | 3.5yrs | sin datos | sin datos | |
| Chief Regulatory Officer | 1.4yrs | sin datos | sin datos | |
| Chief Strategy Officer | 1.4yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos | |
| Vice President of Research and Early Development | no data | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de OVID no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.3yrs | US$1.93m | 1.93% $ 11.0m | |
| CEO, President & Director | less than a year | US$1.02m | 0.032% $ 180.9k | |
| Chairman of the Scientific & Clinical Advisory Board | 5.3yrs | sin datos | sin datos | |
| Independent Director | 9.2yrs | US$86.27k | 0% $ 0 | |
| Lead Independent Director | 10.8yrs | US$105.75k | 0.0045% $ 25.8k | |
| Member of Scientific & Clinical Advisory Board | 9.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.1yrs | sin datos | sin datos | |
| Independent Director | 4.8yrs | US$69.94k | 0.0090% $ 51.5k | |
| Member of Scientific Advisory Board | 2.1yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.1yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.1yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.6yrs | sin datos | sin datos |
Junta con experiencia: La junta directiva de OVID se considera experimentada (3.7 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/20 21:54 |
| Precio de las acciones al final del día | 2026/08/20 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ovid Therapeutics Inc. está cubierta por 16 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |